The search for endothelium friendly stents.
The concern regarding late-stent thrombosis with the use of drug-eluting, stents provides the basis for an examination of alternative approaches to stent design. This article outlines the biological mechanisms behind the thrombosis and hence provides a framework for understanding the types of drug actions that will be required for the next generation of stents.
McCormick
C
C
Strathclyde Institute of Pharmacy and Biomedical Sciences University of Strathclyde, Glasgow, UK. christopher.mccormick@strath.ac.uk
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001158:Arteries / Q000503:physiopathology; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism* / Q000637:transplantation; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D004958:Estradiol / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D017239:Paclitaxel / Q000627:therapeutic use; D012038:Regeneration; D020123:Sirolimus / Q000627:therapeutic use; D013234:Stem Cells / Q000378:metabolism / Q000473:pathology; D015607:Stents; D013927:Thrombosis / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000970:Antineoplastic Agents; D000975:Antioxidants; D042461:Vascular Endothelial Growth Factor A; D009569:Nitric Oxide; D004958:Estradiol; D017239:Paclitaxel; D020123:Sirolimus